A Phase 2 interventional study of IMC-1121B (ramucirumab) and Oxaliplatin in Colorectal Carcinoma, sponsored by Eli Lilly and Company. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Colorectal Neoplasms by Eli Lilly and Company — 4 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Eli Lilly and Company.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 24th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2009, is one of 16 in phase 2, and was the 18th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 37 studies in Colorectal Neoplasms by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Spain
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 19 · Phase 3 3
First in 2002; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 103 across the 34 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Colorectal Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test how long participants with colorectal cancer live without progressive disease when being treated with IMC-1121B (ramucirumab) and the modified FOLFOX-6 chemotherapy.
The purpose of this study is to evaluate the progression-free survival (PFS) in participants with metastatic colorectal cancer when treated with the monoclonal antibody IMC-1121B (ramucirumab) in combination with the modified FOLFOX-6 [folinic acid (FA) + fluorouracil (5-FU) + oxaliplatin, mFOLFOX-6] chemotherapy regimen as first-line therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
Biological: IMC-1121B (ramucirumab) · Drug: Oxaliplatin · Drug: Folinic acid · Drug: 5-FU
8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
Also known as: ramucirumab, LY3009806
85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
400 mg/m² intravenous infusion over 2 hours on Day 1
400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
Progression-Free Survival (PFS)
PFS was defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment.
Time frame: First dose to measured progressive disease or death due to any cause up to 28.1 months
Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)]
ORR is the percentage of participants with a confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.
Time frame: First dose to date of objective progressive disease up to 23.8 months
Overall Survival (OS)
OS was defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, OS was censored on the last date the participant was known to be alive.
Time frame: First dose to death due to any cause up to 28.1 months
Duration of Response
The duration of response was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time of progression or death as a result of any cause. CR or PR is classified by the investigators according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion.
Time frame: Time of response to time of measured progressive disease up to 22.2 months
Number of Participants With IMC-1121B (Ramucirumab)-Related Adverse Events (AEs)
Data presented are the number of participants who experienced AEs of any grade and AEs of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.
Time frame: First dose to 25.2 months
Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs)
Data presented are the number of participants who experienced SAEs, adverse events (AEs) resulting in death and AEs leading to discontinuation of treatment, that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: First dose to 25.2 months
Maximum Concentration (Cmax) at Day 1 of Cycle 1
Due to sparse pharmacokinetic schedule, Cmax was not calculated.
Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)
Area Under the Concentration (AUC) at Day 1 of Cycle 1
Due to sparse pharmacokinetic schedule, AUC was not calculated.
Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)
Half-Life (t1/2) at Day 1 of Cycle 1
Due to sparse pharmacokinetic schedule, t1/2 was not calculated.
Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)
Clearance (CL) at Day 1 of Cycle 1
Due to sparse pharmacokinetic schedule, CL was not calculated.
Time frame: Baseline, 1, 168, and 336 hours post infusion on Day 1 (Cycle 1)
Steady State Volume of Distribution (Vss) at Day 1 of Cycle 1
Due to sparse pharmacokinetic schedule, Vss was not calculated.
Time frame: Baseline, 1, 168, and 336 hours post infusion Day 1 (Cycle 1)
Maximum Concentration (Cmax) at Day 1 of Cycles 5, 9, 13, 17, and 21
Due to sparse pharmacokinetic schedule, Cmax was not calculated.
Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)
Area Under the Concentration (AUC) at Day 1 of Cycles 5, 9, 13, 17, and 21
Due to sparse pharmacokinetic schedule, AUC was not calculated.
Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)
Half-Life (t1/2) at Day 1 of Cycles 5, 9, 13, 17, and 21
Due to sparse pharmacokinetic schedule, t1/2 was not calculated.
Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)
Clearance (CL) at Day 1 of Cycles 5, 9, 13, 17, and 21
Due to sparse pharmacokinetic schedule, CL was not calculated.
Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)
Steady State Volume of Distribution (Vss) at Day 1 of Cycles 5, 9, 13, 17, and 21
Due to sparse pharmacokinetic schedule, Vss was not calculated.
Time frame: Baseline and 1 hour post infusion on Day 1 (Cycles 5, 9, 13, 17, and 21)
Serum Anti-IMC-1121B (Immunogenicity) at Day 1
Data presented are the number of participants with treatment emergent anti-IMC-112B antibodies.
Time frame: Day 1 (Cycles 1, 5, 9, and 30-day follow-up)
| Milestone | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Started | 48 |
| Received any amount of study drug | 48 |
| Completed | 48 |
| Not completed | 0 |
PFS was defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment.
| months | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Progression-Free Survival (PFS) | 11.5 (8.6 to 13.1) |
ORR is the percentage of participants with a confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.
| percentage of participants | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Percentage of Participants With Complete Response or Partial Response [Objective Response Rate (ORR)] | 58.3 (43.21 to 72.39) |
OS was defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, OS was censored on the last date the participant was known to be alive.
| months | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Overall Survival (OS) | 20.4 (18.5 to 25.1) |
The duration of response was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time of progression or death as a result of any cause. CR or PR is classified by the investigators according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion.
| months | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Duration of Response | 11.0 (6.9 to 12.6) |
Data presented are the number of participants who experienced AEs of any grade and AEs of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.
| participants | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Related AEs | 45 |
| Related AEs of Grade ≥3 | 19 |
| Related AE resulting in death | 2 |
| Related AE leading to discontinuation | 11 |
Data presented are the number of participants who experienced SAEs, adverse events (AEs) resulting in death and AEs leading to discontinuation of treatment, that were considered to be related to IMC-1121B (ramucirumab) by the investigators. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| participants | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Number of Participants With IMC-1121B (Ramucirumab)-Related Severe Adverse Events (SAEs) | 10 |
Due to sparse pharmacokinetic schedule, Cmax was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, AUC was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, t1/2 was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, CL was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, Vss was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, Cmax was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, AUC was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, t1/2 was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, CL was not calculated.
No measurements were reported for this outcome.
Due to sparse pharmacokinetic schedule, Vss was not calculated.
No measurements were reported for this outcome.
Data presented are the number of participants with treatment emergent anti-IMC-112B antibodies.
| participants | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Cycle 1 (n=39) | 0 |
| Cycle 5 (n=33) | 2 |
| Cycle 9 (n=25) | 0 |
| 30-day Follow-up (n=17) | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMC-1121B (Ramucirumab) + mFOLFOX-6 | — | 18/48 (37.5%) | 47/48 (97.9%) |
| Event | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| OVARIAN TORSIONReproductive system and breast disorders | 1/23 |
| DISEASE PROGRESSIONGeneral disorders | 2/48 |
| PYREXIAGeneral disorders | 2/48 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 2/48 |
| COAGULOPATHYBlood and lymphatic system disorders | 1/48 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 1/48 |
| NEUTROPENIABlood and lymphatic system disorders | 1/48 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/48 |
| CARDIO-RESPIRATORY ARRESTCardiac disorders | 1/48 |
| ABDOMINAL PAINGastrointestinal disorders | 1/48 |
| Event | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| ASTHENIAGeneral disorders | 35/48 |
| DIARRHOEAGastrointestinal disorders | 32/48 |
| NEUROTOXICITYNervous system disorders | 32/48 |
| NEUTROPENIABlood and lymphatic system disorders | 27/48 |
| HYPERTENSIONVascular disorders | 27/48 |
| MUCOSAL INFLAMMATIONGeneral disorders | 26/48 |
| DYSAESTHESIANervous system disorders | 23/48 |
| NAUSEAGastrointestinal disorders | 21/48 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 17/48 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 15/48 |
All participants who received any amount of study drug.
| Age, Categorical(Participants) | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 31 |
| >=65 years | 17 |
| Sex: Female, Male(Participants) | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Female | 23 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 43 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 48 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | IMC-1121B (Ramucirumab) + mFOLFOX-6 |
|---|---|
| Canada | 5 |
| Spain | 43 |
The record gives a start of Apr 2009, a primary completion of Apr 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 2 months after primary completion. A results delay was requested in Jul 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab